E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjective memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003729 |
E.1.2 | Term | Attention concentration difficulty |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the efficacy of 10mg memantine in comparison to placebo measured by the CogState computer-based neuropsychological test battery [C-NTB], Everyday Cognition 39 [ECog 39], and Hospital Anxiety and Depression Scale [HADS] |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent obtained from the subject, 2. Understanding of study procedures and willingness to abide by all procedures during the course of the study, 3. Age ≥50 and ≤80, 4. Subjective worsening of memory, concentration or attention problems for longer than 6 months, 5. Woman of childbearing potential must be using a highly effective method of birth control, 6. Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject, 7.“Patient Global Impression Severity” (PGI-S) score of ≥3, 8. Experience of the memory, concentration or attention problems at least four times per week, 9. MiniCog score of 3 or more |
|
E.4 | Principal exclusion criteria |
1. Memory, concentration or attention problems interfere with basic daily activities, 2. Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia). 3. Epilepsy or history of epileptic fits (inclusion questionnaire, 4. Severe or acute mental illness (depression or anxiety), 5. Significant systemic illness, such as cancer, kidney failure, severe hepatic impairment, uncontrolled diabetes, 6. Heart attack, heart failure, arrhythmia or carotid stenosis within the last 6 months, 7. History of stroke or transient ischaemic attacks within the last 6 months, 8. Diagnosed pulmonary, gastrointestinal, hepatic, endocrine, untreated B12, TSH or folate deficiencies, 9. Sleep apnea, 10. Weight below 40kg or above 100kg, 11. Previous or current treatment with memantine or participation in an investigational study with memantine, 12. Con- current use of medication that could have effects on cognition ( seelist in the protocol, 8.3), 13. Taking any medications that are contra-indicated in combination with memantine(see SmPC), 14. Known or suspected history of alcoholism or drug abuse within the past 2 years, 15. Known hypersensitivity to the IP or reference, or any of their formulation ingredients, 16. Subject who is imprisoned or is lawfully kept in an institution, 17. Employee or direct relative of an employee of the CRO, the study site, or Merz, 18. Participation in a clinical study for an IP within the previous 90 days prior to visit 2, 19. Previous participation in this clinical study, 20. Clinically significant laboratory results, which may indicate a cause for cognitive symptoms |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is defined as “Patient Global Impression of Change” (PGI-C) at visit 4. The primary efficacy analysis is the statistical comparison between the placebo group and the memantine group at Visit 4 in the Full Analysis Set [FAS] where missing values will be imputed using the Last observation carried forward [LOCF] approach. The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model, with treatment group, “Patient Global Impression Severity” (PGI-S) at screening, gender, age, education, and pooled center as factors. Additionally a reduced ANCOVA model with treatment group and pooled centers as factors will be used. To consider a possible violation of the assumptions of the non-parametric test a Cochan-Mantel-Haenszel test with modified ridit scores stratified by pooled centers will be performed. Furthermore a responder analysis using a logistic regression model will be performed with treatment group, PGI-S at screening, gender, age, education, and pooled centre as independent variables as well as a reduced responder analysis using treatment group and pooled center as independent variables. Response is defined as any improvement in the Subject Global Assessment of Change. Additionally summary statistics will be provided for raw values and the change to Visit 4. Sensitivity analyses of the results will be based on the FAS using observed cases, on the PPS using LOCF and on the PPS using observed cases.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last visit of the last subject undergoing the trial.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |